OCUL
Price
$12.21
Change
-$0.09 (-0.73%)
Updated
Aug 8 closing price
Capitalization
2.12B
93 days until earnings call
RNA
Price
$46.29
Change
-$1.23 (-2.59%)
Updated
Aug 8 closing price
Capitalization
5.58B
94 days until earnings call
Interact to see
Advertisement

OCUL vs RNA

Header iconOCUL vs RNA Comparison
Open Charts OCUL vs RNABanner chart's image
Ocular Therapeutix
Price$12.21
Change-$0.09 (-0.73%)
Volume$2.02M
Capitalization2.12B
Avidity Biosciences
Price$46.29
Change-$1.23 (-2.59%)
Volume$4.93M
Capitalization5.58B
OCUL vs RNA Comparison Chart in %
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. RNA commentary
Aug 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Hold and RNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 09, 2025
Stock price -- (OCUL: $12.21 vs. RNA: $46.29)
Brand notoriety: OCUL and RNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 82% vs. RNA: 186%
Market capitalization -- OCUL: $2.12B vs. RNA: $5.58B
OCUL [@Biotechnology] is valued at $2.12B. RNA’s [@Biotechnology] market capitalization is $5.58B. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileRNA’s FA Score has 0 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • RNA’s FA Score: 0 green, 5 red.
According to our system of comparison, both OCUL and RNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 3 TA indicator(s) are bullish while RNA’s TA Score has 6 bullish TA indicator(s).

  • OCUL’s TA Score: 3 bullish, 5 bearish.
  • RNA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RNA is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а +2.43% price change this week, while RNA (@Biotechnology) price change was +28.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.25%. For the same industry, the average monthly price growth was +6.85%, and the average quarterly price growth was +13.24%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

RNA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+0.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNA($5.58B) has a higher market cap than OCUL($2.12B). RNA YTD gains are higher at: 59.182 vs. OCUL (42.974). OCUL has higher annual earnings (EBITDA): -176.35M vs. RNA (-430.35M). RNA has more cash in the bank: 1.38B vs. OCUL (350M). RNA has less debt than OCUL: RNA (5.97M) vs OCUL (76.2M). OCUL has higher revenues than RNA: OCUL (59.6M) vs RNA (8.93M).
OCULRNAOCUL / RNA
Capitalization2.12B5.58B38%
EBITDA-176.35M-430.35M41%
Gain YTD42.97459.18273%
P/E RatioN/AN/A-
Revenue59.6M8.93M668%
Total Cash350M1.38B25%
Total Debt76.2M5.97M1,276%
FUNDAMENTALS RATINGS
OCUL: Fundamental Ratings
OCUL
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
PROFIT vs RISK RATING
1..100
80
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
OCULRNA
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
N/A
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AUERX14.40N/A
N/A
Auer Growth
TSFYX14.53N/A
N/A
Touchstone Small Cap Y
UMEMX15.26N/A
N/A
Columbia Emerging Markets Inst
JMVZX32.61N/A
N/A
JPMorgan Mid Cap Value R2
FMIUX38.06N/A
N/A
FMI Common Stock Institutional

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-0.73%
EYPT - OCUL
65%
Loosely correlated
+1.59%
RVMD - OCUL
56%
Loosely correlated
+0.14%
DNLI - OCUL
55%
Loosely correlated
-1.90%
IDYA - OCUL
55%
Loosely correlated
+3.08%
NRIX - OCUL
53%
Loosely correlated
-2.28%
More

RNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNA has been loosely correlated with DYN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if RNA jumps, then DYN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNA
1D Price
Change %
RNA100%
-2.59%
DYN - RNA
58%
Loosely correlated
-0.27%
ACLX - RNA
56%
Loosely correlated
-0.91%
BEAM - RNA
53%
Loosely correlated
-1.34%
RVMD - RNA
52%
Loosely correlated
+0.14%
IDYA - RNA
52%
Loosely correlated
+3.08%
More